|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Aminex Therapeutics, Inc.
| | | Phone: | (425) 486-6671 | Fax: | (208) 977-6019 | Year Established: | 2008 | Employees: | 5 | Main Contact: | Mark R. Burns, Ph.D., President & CSO | | Other Contacts: | Tom Graham, COO Michael G. Palfreyman, PhD, DSc, MRPharmS, Senior VP, Drug Development Jim Skaggs, Chairman & CEO
| | Company Description | Aminex Therapeutics is developing Polyamine-Blocker Therapy (PaBT™) as a product for cancer treatment. PaBT™ works by removing a component from cancer cells that is critical for their growth and metastasis. Aminex discovered that depriving the tumor of this component induces a robust and durable immune response; allowing the immune system to recognize and attack the cancer and provide tumor-specific activity. Aiming to join the recent approvals of Ipilimumab (Yervoy, Bristol-Myers Squibb, 2011) and Provenge (Dendreon, 2010) several immunotherapy approaches are under intense development efforts by BioPharma companies. PaBT™ represents an 'off-the-shelf' small molecule immunotherapeutic approach. Aminex’s hopes to join this group and transform the way cancer is treated. | |
|
|
|
|
|